TY  - GEN
AU  - Fu,Kai
AU  - Corbley,Michael J
AU  - Sun,Lihong
AU  - Friedman,Jessica E
AU  - Shan,Feng
AU  - Papadatos,James L
AU  - Costa,Donald
AU  - Lutterodt,Frank
AU  - Sweigard,Harry
AU  - Bowes,Scott
AU  - Choi,Michael
AU  - Boriack-Sjodin,P Ann
AU  - Arduini,Robert M
AU  - Sun,Dongyu
AU  - Newman,Miki N
AU  - Zhang,Xiamei
AU  - Mead,Jonathan N
AU  - Chuaqui,Claudio E
AU  - Cheung,H-Kam
AU  - Zhang,Xin
AU  - Cornebise,Mark
AU  - Carter,Mary Beth
AU  - Josiah,Serene
AU  - Singh,Juswinder
AU  - Lee,Wen-Cherng
AU  - Gill,Alan
AU  - Ling,Leona E
TI  - SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model
SN  - 1524-4636
PY  - 2008///0421
KW  - Activin Receptors, Type I
KW  - antagonists & inhibitors
KW  - Adenosine Triphosphate
KW  - metabolism
KW  - Administration, Oral
KW  - Animals
KW  - Azabicyclo Compounds
KW  - administration & dosage
KW  - Binding Sites
KW  - Carotid Artery Injuries
KW  - drug therapy
KW  - Cell Line
KW  - Fibroblasts
KW  - drug effects
KW  - Fibrosis
KW  - Humans
KW  - Male
KW  - Myoblasts, Smooth Muscle
KW  - Protein Kinase Inhibitors
KW  - Protein Serine-Threonine Kinases
KW  - Rats
KW  - Rats, Sprague-Dawley
KW  - Receptor, Transforming Growth Factor-beta Type I
KW  - Receptors, Transforming Growth Factor beta
KW  - Transforming Growth Factor beta
KW  - physiology
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1161/ATVBAHA.107.158030
ER  -